Literature DB >> 21284281

Generalized acanthosis nigricans related to type B insulin resistance syndrome: a case report.

Ki-Heon Jeong1, Seung-Joon Oh, Suk Chon, Mu-Hyoung Lee.   

Abstract

Acanthosis nigricans (AN) is a cutaneous marker for many underlying states such as endocrine abnormality, obesity, certain drugs, and malignancy. Generalized AN is a rare condition and is commonly seen in adults with an underlying malignancy. The type B insulin resistance syndrome, a rare autoimmune disorder, is caused by the autoantibodies to the insulin receptor. Patients typically present with hyperglycemia but also may present with hypoglycemia. We report a rare case of a 36-year-old man with generalized AN and type B insulin resistance syndrome with hypoglycemia.

Entities:  

Mesh:

Year:  2010        PMID: 21284281

Source DB:  PubMed          Journal:  Cutis        ISSN: 0011-4162


  5 in total

Review 1.  Type B insulin resistance syndrome induced by systemic lupus erythematosus and successfully treated with intravenous immunoglobulin: case report and systematic review.

Authors:  Sigong Zhang; Guochun Wang; Jinping Wang
Journal:  Clin Rheumatol       Date:  2012-10-03       Impact factor: 2.980

2.  The effects of IGF1 on the melanogenesis in alpaca melanocytes in vitro.

Authors:  Shuaipeng Hu; Yu Liu; Shanshan Yang; Kaiyuan Ji; Xuexian Liu; Junzhen Zhang; Ruiwen Fan; Changsheng Dong
Journal:  In Vitro Cell Dev Biol Anim       Date:  2016-05-12       Impact factor: 2.416

Review 3.  Current treatment options for acanthosis nigricans.

Authors:  Nupur U Patel; Catherine Roach; Hossein Alinia; William W Huang; Steven R Feldman
Journal:  Clin Cosmet Investig Dermatol       Date:  2018-08-07

Review 4.  An approach to acanthosis nigricans.

Authors:  Meghana Madhukar Phiske
Journal:  Indian Dermatol Online J       Date:  2014-07

5.  Association of Acanthosis Nigricans and Acrochordon with Insulin Resistance: A Cross-Sectional Hospital-Based Study from North India.

Authors:  Satyendra K Singh; Neeraj K Agrawal; Ajay K Vishwakarma
Journal:  Indian J Dermatol       Date:  2020 Mar-Apr       Impact factor: 1.494

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.